0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Letters   |    
Rapid Responses of High-Dose Combined Therapy of Escitalopram and Aripiprazole in a Case of Severe Obsessive Compulsive Disorder With Delusion
Yi-Cheng Hou, M.Sc.; Chien-Han Lai, M.D.
The Journal of Neuropsychiatry and Clinical Neurosciences 2014;26:E44-E45. doi:10.1176/appi.neuropsych.13050103
View Author and Article Information

The authors report no financial relationships with commercial interests.

Dept. of Nutrition, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan, ROC

Dept. of Psychiatry, Cheng Hsin General Hospital, Taipei City, Taiwan, ROC
Dept. of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan, ROC

Send correspondence to Dr. Lai; e-mail: stephenlai99@gmail.com

Copyright © 2014 by the American Psychiatric Association

Extract

To the Editor: The standard treatment of obsessive compulsive disorder (OCD) usually means antidepressants.1 A low dose of antipsychotic can be an option of augmentation therapy for treatment-resistant OCD. We want share the experience of a severe OCD patient with delusion, who had rapid response after combination of high-dose escitalopram and aripiprazole for 2 weeks.

Figures in this Article

First Page Preview

View Large
First page PDF preview
Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

+

References

Koran  LM;  Hanna  GL;  Hollander  E  et al: American Psychiatric Association:  Practice guideline for the treatment of patients with obsessive-compulsive disorder.  Am J Psychiatry 2007; 164(Suppl):5–53
[PubMed]
 
Dold  M;  Aigner  M;  Lanzenberger  R  et al:  Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.  Int J Neuropsychopharmacol 2013; 16:557–574
[CrossRef] | [PubMed]
 
Lai  CH:  Aripiprazole treatment in an adolescent patient with chronic motor tic disorder and treatment-resistant obsessive-compulsive disorder.  Int J Neuropsychopharmacol 2009; 12:1291–1293
[CrossRef] | [PubMed]
 
Muscatello  MR;  Bruno  A;  Pandolfo  G  et al:  Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.  J Clin Psychopharmacol 2011; 31:174–179
[CrossRef] | [PubMed]
 
Sayyah  M;  Sayyah  M;  Boostani  H  et al:  Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial).  Depress Anxiety 2012; 29:850–854
[CrossRef] | [PubMed]
 
Perani  D;  Garibotto  V;  Gorini  A  et al:  In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder.  Neuroimage 2008; 42:306–314
[CrossRef] | [PubMed]
 
Lawler  CP;  Prioleau  C;  Lewis  MM  et al:  Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes.  Neuropsychopharmacology 1999; 20:612–627
[CrossRef] | [PubMed]
 
Giorgetti  M;  Tecott  LH:  Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems.  Eur J Pharmacol 2004; 488:1–9
[CrossRef] | [PubMed]
 
Pae  CU;  Serretti  A;  Patkar  AA  et al:  Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence.  CNS Drugs 2008; 22:367–388
[CrossRef] | [PubMed]
 
Winter  C;  Heinz  A;  Kupsch  A  et al:  Aripiprazole in a case presenting with Tourette syndrome and obsessive-compulsive disorder.  J Clin Psychopharmacol 2008; 28:452–454
[CrossRef] | [PubMed]
 
Yokoi  F;  Gründer  G;  Biziere  K  et al:  Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.  Neuropsychopharmacology 2002; 27:248–259
[CrossRef] | [PubMed]
 
References Container
+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Books
Textbook of Traumatic Brain Injury, 2nd Edition > Chapter 35.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 9.  >
Textbook of Psychotherapeutic Treatments > Chapter 6.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 39.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 37.  >
Topic Collections
Psychiatric News
Read more at Psychiatric News >>
APA Guidelines